Novartis India Limited (NOVARTIND.BO)
INR 792.0
(3.42%)
INR 792.0
(3.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.89 Billion INR | -28287.08% |
| 2022 | 20.9 Million INR | 101.56% |
| 2021 | -1.34 Billion INR | -2220.21% |
| 2020 | -57.9 Million INR | 46.54% |
| 2019 | -108.3 Million INR | 87.66% |
| 2018 | -877.6 Million INR | -133.22% |
| 2017 | -376.3 Million INR | 50.22% |
| 2016 | -755.9 Million INR | -300.16% |
| 2015 | -188.9 Million INR | 97.03% |
| 2014 | -6.37 Billion INR | -3716.84% |
| 2013 | -166.9 Million INR | 57.34% |
| 2012 | -391.2 Million INR | 52.73% |
| 2011 | -827.5 Million INR | 6.41% |
| 2010 | -884.2 Million INR | -55.34% |
| 2009 | -569.19 Million INR | -6.48% |
| 2008 | -534.55 Million INR | -262.14% |
| 2007 | -147.61 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -191.2 Million INR | -103.27% |
| 2024 Q1 | 5.84 Billion INR | 199.3% |
| 2023 Q1 | 5.54 Billion INR | 26427.27% |
| 2023 Q2 | -315.4 Million INR | -105.69% |
| 2023 Q3 | 4.9 Billion INR | 1653.8% |
| 2023 Q4 | -5.89 Billion INR | -220.21% |
| 2023 FY | -5.89 Billion INR | -28287.08% |
| 2022 Q2 | 143.7 Million INR | -97.22% |
| 2022 FY | 20.9 Million INR | 101.56% |
| 2022 Q3 | 5.65 Billion INR | 3832.78% |
| 2022 Q4 | 20.9 Million INR | -99.63% |
| 2022 Q1 | 5.16 Billion INR | 484.32% |
| 2021 Q4 | -1.34 Billion INR | -126.16% |
| 2021 Q2 | -226.3 Million INR | -104.55% |
| 2021 Q1 | 4.97 Billion INR | 8690.85% |
| 2021 FY | -1.34 Billion INR | -2220.21% |
| 2021 Q3 | 5.13 Billion INR | 2369.11% |
| 2020 Q1 | 5.8 Billion INR | 5459.1% |
| 2020 Q3 | 5.12 Billion INR | 1484.25% |
| 2020 FY | -57.9 Million INR | 46.54% |
| 2020 Q2 | 323.8 Million INR | -94.42% |
| 2020 Q4 | -57.9 Million INR | -101.13% |
| 2019 Q1 | 6.1 Billion INR | 795.65% |
| 2019 FY | -108.3 Million INR | 87.66% |
| 2019 Q3 | 6.49 Billion INR | 8650.81% |
| 2019 Q2 | 74.2 Million INR | -98.78% |
| 2019 Q4 | -108.3 Million INR | -101.67% |
| 2018 Q3 | 7 Billion INR | 1990.98% |
| 2018 Q2 | -370.2 Million INR | -104.79% |
| 2018 Q1 | 7.73 Billion INR | 2155.57% |
| 2018 FY | -877.6 Million INR | -133.22% |
| 2018 Q4 | -877.6 Million INR | -112.54% |
| 2017 Q4 | -376.3 Million INR | -104.48% |
| 2017 Q3 | 8.39 Billion INR | 1264.69% |
| 2017 FY | -376.3 Million INR | 50.22% |
| 2017 Q1 | 8.34 Billion INR | 1203.89% |
| 2017 Q2 | -720.7 Million INR | -108.64% |
| 2016 Q1 | 11.13 Billion INR | 5993.38% |
| 2016 Q4 | -755.9 Million INR | -109.07% |
| 2016 Q2 | -8.14 Billion INR | -173.16% |
| 2016 FY | -755.9 Million INR | -300.16% |
| 2016 Q3 | 8.33 Billion INR | 202.28% |
| 2015 Q4 | -188.9 Million INR | -101.92% |
| 2015 FY | -188.9 Million INR | 97.03% |
| 2015 Q3 | 9.85 Billion INR | 200.0% |
| 2015 Q2 | -9.85 Billion INR | -217.51% |
| 2015 Q1 | 8.38 Billion INR | 231.63% |
| 2014 Q1 | 168.1 Million INR | 200.72% |
| 2014 FY | -6.37 Billion INR | -3716.84% |
| 2014 Q4 | -6.37 Billion INR | -3581.04% |
| 2014 Q3 | 183 Million INR | 200.0% |
| 2014 Q2 | -183 Million INR | -208.86% |
| 2013 Q2 | -212.6 Million INR | -154.1% |
| 2013 Q4 | -166.9 Million INR | -178.5% |
| 2013 FY | -166.9 Million INR | 57.34% |
| 2013 Q3 | 212.6 Million INR | 200.0% |
| 2013 Q1 | 393 Million INR | 200.46% |
| 2012 FY | -391.2 Million INR | 52.73% |
| 2012 Q4 | -391.2 Million INR | -296.78% |
| 2012 Q2 | -197.6 Million INR | 0.0% |
| 2012 Q3 | 198.8 Million INR | 200.61% |
| 2011 Q4 | -827.5 Million INR | 0.0% |
| 2011 FY | -827.5 Million INR | 6.41% |
| 2010 FY | -884.2 Million INR | -55.34% |
| 2009 FY | -569.19 Million INR | -6.48% |
| 2008 FY | -534.55 Million INR | -262.14% |
| 2007 FY | -147.61 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alkem Laboratories Limited | -1.6 Billion INR | -266.043% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -2267.882% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 252.386% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | -17.53% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 259.508% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -31837.005% |
| Eris Lifesciences Limited | 13.8 Billion INR | 142.669% |
| FDC Limited | -57.75 Million INR | -10100.686% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | -107.239% |
| Ipca Laboratories Limited | 11.41 Billion INR | 151.608% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -323.841% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 404.777% |
| Laurus Labs Limited | 24.38 Billion INR | 124.159% |
| Lupin Limited | 17.19 Billion INR | 134.266% |
| Medicamen Biotech Limited | 160.31 Million INR | 3774.68% |
| Medico Remedies Limited | 78.67 Million INR | 7587.703% |
| Megasoft Limited | 1.28 Billion INR | 558.255% |
| NATCO Pharma Limited | -5.81 Billion INR | -1.274% |
| Piramal Pharma Limited | 42.27 Billion INR | 113.935% |
| Sigachi Industries Limited | 859.94 Million INR | 785.052% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 158.741% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 91.871% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 4163.5% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 12848.263% |
| Themis Medicare Limited | 764.96 Million INR | 870.117% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 118.508% |
| Valiant Laboratories Limited | -295.03 Million INR | -1896.766% |
| Wanbury Limited | 1.1 Billion INR | 632.709% |
| Windlas Biotech Limited | -273.04 Million INR | -2057.596% |
| ZIM Laboratories Limited | 983.6 Million INR | 698.93% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 250.59% |
| Ajanta Pharma Limited | -954.9 Million INR | -516.934% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | -41.85% |
| Achyut Healthcare Limited | -3.74 Million INR | -157163.748% |
| Lasa Supergenerics Limited | 205.79 Million INR | 2962.55% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -525.515% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 325.548% |
| Alpa Laboratories Limited | 35.36 Million INR | 16758.937% |
| Gufic Biosciences Limited | 3.19 Billion INR | 284.424% |
| Ind-Swift Limited | 9.5 Billion INR | 161.956% |
| Indoco Remedies Limited | 6.47 Billion INR | 190.964% |
| Hester Biosciences Limited | 2.29 Billion INR | 357.17% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -408.84% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 278.575% |
| RPG Life Sciences Limited | -364.7 Million INR | -1515.328% |
| Mankind Pharma Limited | -9.9 Billion INR | 40.542% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | -37.474% |
| Unichem Laboratories Limited | 931.91 Million INR | 732.149% |
| Bal Pharma Limited | 1.26 Billion INR | 566.23% |
| Strides Pharma Science Limited | 23.25 Billion INR | 125.33% |
| Venus Remedies Limited | -267.7 Million INR | -2100.635% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 121.761% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 145.621% |
| Divi's Laboratories Limited | -39.77 Billion INR | 85.187% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 195.677% |
| Shilpa Medicare Limited | 9.06 Billion INR | 164.955% |
| Aarti Drugs Limited | 5.54 Billion INR | 206.177% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -434.922% |
| Suven Life Sciences Limited | -1.63 Billion INR | -260.82% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 308.815% |
| Hikal Limited | 7.96 Billion INR | 173.944% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -150.899% |
| Sequent Scientific Limited | 4.17 Billion INR | 240.982% |
| Granules India Limited | 9.28 Billion INR | 163.435% |
| Wockhardt Limited | 18.27 Billion INR | 132.245% |
| Brooks Laboratories Limited | 49.48 Million INR | 12004.82% |
| Neuland Laboratories Limited | -214.05 Million INR | -2652.105% |
| Morepen Laboratories Limited | -231.17 Million INR | -2448.34% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 5007.655% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 703.713% |